THIRD EDITION

Premature Ejaculation Therapeutics Market - Global Outlook and Forecast 2020-2025

PUBLISHED DATE : Apr 2020 | Pages : 269

Up to $1100 off Until Dec 2022

PREMATURE EJACULATION MARKET SIZE TO REACH USD 2 BILLION BY 2025, GROWING AT A CAGR OF 8% DURING THE FORECAST PERIOD

Premature Ejaculation Market Size, Share, & Trends Analysis Report Research Report by Drug Class (SSRIs, PDE5 Inhibitors, Anesthetic Agents, and Others), Route of Administration (ROA) (Oral PE Therapeutics and Topical PE therapeutics), and Geography (APAC, Europe, North America, Latin America, and Middle East & Africa), Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2020-2025

Licence Types What are these?
GET ACTIONABLE INSIGHTS ON HOW COVID-19 IS IMPACTING YOUR BUSINESS
Enquire Now Download Free Sample

Most Exhaustive Report

icon-pages

269 Pages

icon-table

54 Tables

icon-chart

155 Charts

icon-region

5 Regions

icon-country

19 Countries

icon-company

15 Companies

icon-market

3 Market Segment

PREMATURE EJACULATION MARKET REPORT SCOPE

Report Attribute Details
Market Size (Revenue) USD 2 BILLION (2025)
CAGR 8% (2020-2025)
Base Year 2019
Forecast Year 2020-2025
Market Segments Drug Class (SSRIs, PDE5 Inhibitors, Anesthetic Agents, and Others), Route of Administration (ROA) (Oral PE Therapeutics and Topical PE therapeutics)
Geographic Analysis APAC, Europe, North America, Latin America, and Middle East & Africa
Countries Covered US, Canada, Germany, France, UK, Italy, Spain, Japan, China, India, South Korea, Brazil, Mexico, Argentina, Turkey, Saudi Arabia, South Africa, and Iran

INDUSTRY INSIGHTS

The global premature ejaculation (PE) market size will reach USD 2 billion in 2025 is expected to grow at a steady CAGR during the forecast period. The market growth can be mainly attributed to the growing prevalence of premature ejaculation (PE) among men globally. PE is the most prevalent sexual dysfunction among men the world over. With the presence of a single approved oral drug, the PE therapeutics market is dominated by off-label drugs, generic versions of patent expired drugs, and OTC formulations, both regionally as well as globally. The increasing demand for several off-label and generic drugs is a primary factor driving the growth of the market. The treatment with off-label drugs belonging to SSRIs and topical formulations has revolutionized the treatment approach. Several vendors are offering off-label drugs that belong to different drug classes such as SSRIs and PDE5 inhibitors and OTC topical creams/sprays for treatment. Therefore, the demand for such drugs is likely to increase at a steady rate globally.

Another advance is the advent of metered-dose delivery systems. Several OTC anesthetic sprays are formulated to deliver the drug through a metered-dose administration. Metered-dose delivery systems deliver lidocaine and prilocaine in base form without organic solvents. Such drugs can be easily removed before vaginal penetration, thus circumventing the need for a condom that most patients find uncomfortable. Hence, such advanced formulations are likely to boost the future growth of the global PE therapeutics market.

SNIPPETS

  • North America is likely to dominate the global premature ejaculation therapeutics market, APAC is expected to grow at the highest CAGR during the forecast period due to the increase in disease awareness and the rise in disease prevalence in the region.
  • The SSRIs drug class segment is expected to grow due to the availability of a broad range of oral therapies and preference for oral therapies (SSRIs) as first-line treatment drugs.
  • The topical ROA segment is likely to witness high growth than the oral ROA segment on account of easy availability and low side-effects.

PREMATURE EJACULATION MARKET SEGMENTATION

This research report offers a detailed segmentation by

  • Drugs
  • ROA
  • Geography

INSIGHTS BY DRUG

The SSRIs segment is likely to retain its market dominance during the forecast period. SSRIs are considered as effective drugs for the treatment of PE, and they majorly include paroxetine, sertraline, fluoxetine, citalopram, escitalopram, and dapoxetine. Several evidence-based studies have demonstrated the safety and efficacy of SSRIs in delaying ejaculation, which ensures their role as first-line agents for the treatment of lifelong and acquired PE. The growth of the segment is likely to be facilitated by an increase in the number of countries gaining approval for the use of Priligy. The increased recommendation of SSRIs by healthcare professionals is one of the key factors for the growth of the segment worldwide.  

The increase in the share of the PDE5 inhibitors segment can be mainly attributed to the brand value of existing PDE5 inhibitor drugs, which facilitate high uptake among patients, especially for self-management. Anesthetic agents have proved effective and are generally tolerated for patients with PE. Several topical anesthetics are inexpensive and readily available from pharmacies, thereby allowing them an easy medication to buy. The segment is likely to witness a higher CAGR during the forecast period than other drug therapies. The expected launch of new licensed/unlicensed OTC products worldwide is the prime factor enhancing growth.

INSIGHTS BY ROA

Oral therapeutics consists of tablets, capsules, solutions, and suspensions. Several oral agents, specifically SSRIs, tramadol, and dapoxetine, have proven effective and safe for the treatment of PE. Hence, several HCPs are recommending oral therapeutics as a primary treatment option to manage premature ejaculation. A daily dose of oral therapies has exhibited improved and enhanced efficacy over topical therapies. Therefore, the demand for oral therapeutics is increasing at a steady-state worldwide. Moreover, the growing pervasiveness of PE and the increasing uptake of generic off-label medications are the key factors enabling the growth of the oral ROA segment. 

Topical medications refer to the drugs that are applied to the skin and include creams, gels, sprays, powders, emulsion, solutions, and ointments. These drugs are often used as “a needed option” for efficient management of PE and erectile dysfunction. Therefore, the segment accounts for a smaller share than oral therapeutics. Easy availability of several topical medicines at multiple sales channels acts as one of the key factors, which boosts the product uptake of topical therapies in the vast majority of patients.

INSIGHTS BY GEOGRAPHY

North America is the major revenue contributor to the global premature ejaculation therapeutics market. The presence of a large disease population, coupled with better access to healthcare, especially OTC drugs, and increased focus on sexual wellness products is the primary factor for high shares. The strong presence of key vendors is also another reason for high product uptake in the region.

The presence of major vendors, better disease awareness, high healthcare spending on sexual wellbeing is the primary factor for high market share in this region. Germany, the UK, France, Italy, and Spain are the major revenue contributors. The increasing treatment-seeking population will mainly drive the market in Europe due to improved PE awareness and increased patient focus on healthy sexual well-being.

A low treatment-seeking population associated with social stigma in select regions, lack of awareness, and comparatively less access to healthcare services, especially in developing countries, are few factors that limit the growth of the market in this region. Japan, India, China, Australia, and South Korea are the major revenue contributors in the region. 

The Latin American market is expected to grow at a higher rate than other regions during the forecast period. A high prevalence of PE, improvement in healthcare spending, an increase in awareness, an increase in uptake of drugs, especially generic off-label drugs and low-cost OTC drugs will fuel the growth of premature ejaculation therapeutics market in this region. The prevalence rate of PE in Latin America is estimated to be higher than in Europe. The average prevalence rate in this region is estimated at 28%. However, an increase in disease awareness, willingness to seek professional help for disease management, high prevalence of chronic psychological and other male sexual health disorders, especially ED, are contributing to the growth of the PE therapeutics market in this region.

Low access to healthcare facilities, inadequacy in a number of specialized health professionals, and lack of awareness about the disease and its treatment options are the key reasons for the low market size of premature ejaculation treatment despite high market potential. Therefore, the market is expected to witness slow growth than other regions in the coming years.  

INSIGHTS BY VENDORS

The global premature ejaculation therapeutics market is fairly fragmented and is characterized by the presence of both pharmaceutical companies and generic manufacturers offering off-label branded drugs and generics. Vendors are offering off-label drugs, generic versions, and OTC topical anesthetic agents. Companies offering topical anesthetic drug formulations are gaining widespread popularity than manufacturers offering oral PE therapeutics. Pfizer, Bayer, Eli Lilly and Company, and GlaxoSmithKline are also being used as off-label drugs. Therefore, these global players have a significant presence in the market as physicians, especially in select countries such as the US, Germany, and Japan and are prescribing popular brands such as Paxil, Zoloft, Viagra, Levitra, and Cialis as off-label drugs. However, due to their high cost, a broad majority of physicians worldwide are recommending low-cost generic versions of these popular prescription drugs. Therefore, the market has witnessed the entry of many generic manufacturers offering generic drugs of the patent expired drugs at a low price.

The premature ejaculation market research report includes in-depth coverage of the industry analysis with revenue and forecast insights for the following segments:

Segmentation by Drug Class

  • SSRIs
  • PDE5 Inhibitors
  • Anesthetic Agents
  • Others

By ROA

  • Oral PE therapeutics
  • Topical PE therapeutics

By Geography

  • Europe
    • Spain
    • Germany
    • Italy
    • France
    • UK
  • North America
    • US
    • Canada
  • APAC
    • South Korea
    • China
    • Japan
    • Australia
    • India
  • Latin America
    • Brazil
    • Argentina
    • Mexico
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • South Africa
    • Iran

Frequently Asked Questions

What is the global premature ejaculation market size and growth forecast?

Premature ejaculation market size to reach USD 2 billion by 2025, growing at a CAGR of 8% during the forecast period

What are the major factors that are driving the global premature ejaculation market share?

The market growth can be mainly attributed to the growing prevalence of premature ejaculation (PE) among men globally.

Who are the leading vendors in the premature ejaculation market?

Absorption Pharmaceuticals, Innovus Pharmaceuticals, Pfizer, and Plethora Solutions Holdings are leading vendors in the market

Which segment will contribute maximum revenue to the premature ejaculation market?

North America is the major revenue contributor to the global premature ejaculation therapeutics market.

What are the latest industry trends and drivers in the market?

The following factors are likely to contribute to the growth of the premature ejaculation therapeutics market during the forecast period: High Demand for Topical Drug Therapies for PE Treatment, Low Effectiveness of Non-pharmacological PE Treatment, Increasing Awareness Campaigns and Initiatives for PE Treatment, and Advances in PE Drug Formulation Technology

Download Free Sample

The premature ejaculation therapeutics market is expected to grow at a CAGR of over 8% during the period 2019–2025.

 The following factors are likely to contribute to the growth of the premature ejaculation therapeutics market during the forecast period:

  • High Demand for Topical Drug Therapies for PE Treatment
  • Low Effectiveness of Non-pharmacological PE Treatment
  • Increasing Awareness Campaigns and Initiatives for PE Treatment
  • Advances in PE Drug Formulation Technology

 Base Year:                  2019

Forecast Year:           2020–2025

The study considers the present scenario of the premature ejaculation therapeutics market and its market dynamics for the period 2019−2025. It covers a detailed overview of several market growth enablers, restraints, and trends. The study offers both the demand and supply aspects of the market. It profiles and examines leading companies and other prominent companies operating in the market.

Key Vendors

  • Absorption Pharmaceuticals
    • Business Overview
    • Major Product Offerings
    • Key Strengths
    • Key Strategies
    • Key Opportunities
  • Innovus Pharmaceuticals
  • Pfizer
  • Plethora Solutions Holdings

Other Vendors

  • Bayer
    • Business Overview
    • Major Product Offerings
    • Key Strengths
    • Key Strategies
    • Key Opportunities
  • Eli Lilly and Company
  • GlaxoSmithKline
  • MidasCare
  • Momentum Management
  • Pound International
  • Reckitt Benckiser Group
  • Recordati
  • Royalty Pharma
  • Shibari
  • The Menarini Group

Market Segmentation by Drug Class

  • SSRIs
  • PDE5 Inhibitors
  • Anesthetic Agents
  • Others

Market Segmentation by ROA

  • Oral PE therapeutics
  • Topical PE therapeutics

Market Segmentation by Geography

  • Europe
    • Spain
    • Germany
    • Italy
    • France
    • UK
  • North America
    • US
    • Canada
  • APAC
    • South Korea
    • China
    • Japan
    • Australia
    • India
  • Latin America
    • Brazil
    • Argentina
    • Mexico
  • MEA
    • Turkey
    • Saudi Arabia
    • South Africa
    • Iran

 

1 Research Methodology

2 Research Objectives

3 Research Process

4 Scope & Coverage

4.1 Market Definition

4.1.1 Inclusions

4.1.2 Exclusions

4.2 Base Year

4.3 Scope of The Study

4.3.1 Market Segmentation by Geography

5 Report Assumptions & Caveats

5.1 Key Caveats

5.2 Currency Conversion

5.3 Market Derivation

6 Market at a Glance

7 Introduction

7.1 Premature Ejaculation: An Overview

7.1.1 Definition

7.1.2 Disease Overview

7.1.3 Classification of Premature Ejaculation

7.1.4 Symptoms of PE

7.1.5 Etiology of Premature Ejaculation

7.1.6 Epidemiology

7.2 ISSN Guidelines On Premature Ejaculation

7.2.1 Disease Assessment

7.2.2 Treatment Options For Pe

8 CLINICAL TRIAL LANDSCAPE

8.1 Overview

8.1.1 Subjects Selection Criteria for PE Clinical Trials

8.1.2 Clinical Trial Data Evaluation Considerations

8.1.3 Clinical Trial Design Considerations for PE

8.2 Clinical Trial Endpoints

9 Pipeline Landscape

9.1 Overview

9.2 Key Pipeline Drug candidates

9.3 Key Pipeline Molecules

9.3.1 Epelsiban

9.3.2 IX-01

9.3.3 DA-8031

9.3.4 NH02D

9.4 Terminated/Withdrawn Drug Candidates

10 Market Opportunities & Trends

10.1 High Demand for Topical Drug Therapies for PE Treatment

10.2 Presence of High Unmet Demand

10.3 Advancements in PE Drug Formulation Technology

11 Market Growth Enablers

11.1 Rising Prevalence/Incidence of PE

11.2 Wide Accessibility of OTC Drugs & General Off-label Drugs for PE

11.3 Low effectiveness of Non-pharmacological PE Treatment

11.3.1 Major Drawbacks of Non-Pharmacological Treatments

11.4 Increasing Awareness Campaigns & Initiatives for PE Treatment

12 Market Restraints

12.1 Availability of Alternative Treatment Options for PE

12.2 Low Treatment-Seeking Patient Pool

12.3 Adverse Effects of PE Therapeutics

12.4 Clinical Trial Withdrawals/Terminations & Inactive Clinical Studies

13 Market Landscape

13.1 Market Overview

13.2 Market Size & Forecast

13.3 Five Forces Analysis

13.3.1 Threat of New Entrants

13.3.2 Bargaining Power of Suppliers

13.3.3 Bargaining Power of Buyers

13.3.4 Threat of Substitutes

13.3.5 Competitive Rivalry

14 Premature Ejaculation Therapeutics Market by Drug Class

14.1 Market Snapshot & Growth Engine

14.2 Market Overview

14.3 SSRIs

14.3.1 Market Overview

14.3.2 Market Size & Forecast

14.4 PDE5 Inhibitors

14.4.1 Market Overview

14.4.2 Market Size & Forecast

14.5 Anesthetic Agents

14.5.1 Market Overview

14.5.2 Market Size & Forecast

14.6 Others

14.6.1 Market Overview

14.6.2 Market Size & Forecast

15 Premature Ejaculation Therapeutics Market by Route of Administration

15.1 Market Snapshot & Growth Engine

15.2 Market Overview

15.3 Oral

15.3.1 Market Overview

15.3.2 Market Size & Forecast

15.4 Topical

15.4.1 Market Overview

15.4.2 Market Size & Forecast

16 Premature Ejaculation Therapeutics Market by Geography

16.1 Market Snapshot & Growth Engine

16.2 Overview

17 North America

17.1 Market Overview

17.2 Market Size & Forecast

17.3 Drug Class Segmentation

17.3.1 Market Snapshot & Growth Engine

17.4 KEY COUNTRIES

17.4.1 US: Premature Ejaculation Therapeutics Market Size & Forecast

17.4.2 Canada: Market Size & Forecast

18 Europe

18.1 Market Overview

18.2 Market Size & Forecast

18.3 Drug Class Segmentation

18.3.1 Market Snapshot & Growth Engine

18.4 Key Countries

18.4.1 Germany: Market Size & Forecast

18.4.2 UK: Premature Ejaculation Therapeutics Market Size & Forecast

18.4.3 France: Market Size & Forecast

18.4.4 Italy: Premature Ejaculation Therapeutics Market Size & Forecast

18.4.5 Spain: Market Size & Forecast

19 APAC

19.1 Market Overview

19.2 Market Size & Forecast

19.3 Drug Class Segmentation

19.3.1 Market Snapshot & Growth Engine

19.4 Key Countries

19.4.1 Japan: Premature Ejaculation Therapeutics Market Size & Forecast

19.4.2 India: Market Size & Forecast

19.4.3 China: Premature Ejaculation Therapeutics Market Size & Forecast

19.4.4 Australia: Market Size & Forecast

19.4.5 South Korea: Premature Ejaculation Therapeutics Market Size & Forecast

20 Latin America

20.1 Market Overview

20.2 Market Size & Forecast

20.3 Drug Class Segmentation

20.3.1 Market Snapshot & Growth Engine

20.4 Key Countries

20.4.1 Brazil: Premature Ejaculation Therapeutics Market Size & Forecast

20.4.2 Mexico: Market Size & Forecast

20.4.3 Argentina: Premature Ejaculation Therapeutics Market Size & Forecast

21 Middle East & Africa

21.1 Market Overview

21.2 Market Size & Forecast

21.3 Drug Class Segmentation

21.3.1 Market Snapshot & Growth Engine

21.4 Key Countries

21.4.1 Turkey: Premature Ejaculation Therapeutics Market Size & Forecast

21.4.2 Saudi Arabia: Market Size & Forecast

21.4.3 South Africa: Premature Ejaculation Therapeutics Market Size & Forecast

21.4.4 Iran: Market Size & Forecast

22 Competitive Landscape

22.1 Competition Overview

22.2 Market Share Analysis

22.2.1 Absorption Pharmaceuticals

22.2.2 Innovus Pharmaceuticals

22.2.3 Pfizer

22.2.4 Plethora Solutions

23 Key Company Profiles

23.1 Absorption Pharmaceuticals

23.1.1 Business Overview

23.1.2 Product Offerings

23.1.3 Key Strategies

23.1.4 Key Strengths

23.1.5 Key Opportunities

23.2 Innovus Pharmaceuticals

23.2.1 Business Overview

23.2.2 Product Offerings

23.2.3 Key Strategies

23.2.4 Key Strengths

23.2.5 Key Opportunities

23.3 Pfizer

23.3.1 Business Overview

23.3.2 Product Offerings

23.3.3 Key Strategies

23.3.4 Key Strengths

23.3.5 Key Opportunities

23.4 Plethora Solutions Holdings

23.4.1 Business Overview

23.4.2 Product Offerings

23.4.3 Key Strategies

23.4.4 Key Strengths

23.4.5 Key Opportunities

24 Other Prominent Vendors

24.1 Bayer

24.1.1 Business Overview

24.1.2 Product Offerings

24.1.3 Key Strategies

24.1.4 Key Strengths

24.1.5 Key Opportunities

24.2 Eli Lilly and Company

24.2.1 Business Overview

24.2.2 Product Offerings

24.2.3 Key Strategies

24.2.4 Key Strengths

24.2.5 Key Opportunities

24.3 GlaxoSmithKline

24.3.1 Business Overview

24.3.2 Product Offerings

24.3.3 Key Strategies

24.3.4 Key Strengths

24.3.5 Key Opportunities

24.4 MidasCare

24.4.1 Business Overview

24.4.2 Product Offerings

24.4.3 Key Strategies

24.4.4 Key Strengths

24.4.5 Key Opportunities

24.5 Momentum Management

24.5.1 Business Overview

24.5.2 Product Offerings

24.5.3 Key Strategies

24.5.4 Key Strengths

24.5.5 Key Opportunities

24.6 Pound International

24.6.1 Business Overview

24.6.2 Product Offerings

24.6.3 Key Strategies

24.6.4 Key Strengths

24.6.5 Key Opportunities

24.7 Reckitt Benckiser Group

24.7.1 Business Overview

24.7.2 Product Offerings

24.7.3 Key Strategies

24.7.4 Key Strengths

24.7.5 Key Opportunities

24.8 Recordati

24.8.1 Business Overview

24.8.2 Product Offerings

24.8.3 Key Strategies

24.8.4 Key Strengths

24.8.5 Key Opportunities

24.9 Royalty Pharma

24.9.1 Business Overview

24.9.2 Product Offerings

24.9.3 Key Strategies

24.9.4 Key Strengths

24.9.5 Key Opportunities

24.10 Shibari

24.10.1 Business Overview

24.10.2 Product Offerings

24.10.3 Key Strategies

24.10.4 Key Strengths

24.10.5 Key Opportunities

24.11 The Menarini Group

24.11.1 Business Overview

24.11.2 Product Offerings

24.11.3 Key Strategies

24.11.4 Key Strengths

24.11.5 Key Opportunities

25 Report Summary

25.1 Key Takeaways

25.2 Strategic Recommendations

26 Quantitative Summary

26.1 Drug Class

26.2 Route of Administration (RoA)

26.3 Geography

27 Appendix

27.1 Abbreviations

List of Exhibits 

Exhibit 1               Segmentation of Global Premature Ejaculation Therapeutics Market

Exhibit 2               Market Size Calculation Approach 2019

Exhibit 3               Characteristics Associated with PE

Exhibit 4               Classification of PE

Exhibit 5               ISSM Classification of PE

Exhibit 6               Broader Classification of PE

Exhibit 7               Major PE Types

Exhibit 8               Differentiation of Symptoms in Different PE Sub-types

Exhibit 9               Most Common Psychological Causes for PE

Exhibit 10             Common Causative Factors for PE

Exhibit 11             PE Prevalence Rate across Geographies

Exhibit 12             ISSN Recommended Drug Classes for PE Treatment

Exhibit 13             ISSN Recommended Drug Class for the Treatment of PE

Exhibit 14             Key Considerations of PE Clinical Trials

Exhibit 15             Clinical Trial Considerations

Exhibit 16             Key Primary/Secondary Endpoints in PE Clinical Trials

Exhibit 17             Key Hurdles in Research & Innovation of Breakthrough PE Drugs

Exhibit 18             Impact of High Demand for Topical Drug Therapies for PE Treatment

Exhibit 19             Available Topical Forms of PE Topical Therapies

Exhibit 20             Benefits of Topical Drug Delivery System for PE

Exhibit 21             Impact of Presence of High Unmet Demand

Exhibit 22             Impact of Advancements in PE Drug Formulation Technology

Exhibit 23             Impact of Rising Prevalence/Incidence of PE

Exhibit 24             Prevalence Rate of PE in Different Region

Exhibit 25             Comparison of Prevalence Rates of PE and ED in Different Age Groups (%)

Exhibit 26             Number of Men with Premature Ejaculation in US and EU (million)

Exhibit 27             Global Diabetes Prevalence by Region 2015–2040 (million)

Exhibit 28             Global Cancer Incidence 2018

Exhibit 29             Increase in Global Prostate Cancer Incidence by Region 2012–2020 (thousand)

Exhibit 30             Increase in Global ED Prevalence 1995−2025 (million)

Exhibit 31             Impact of Wide Accessibility of OTC Drugs & General Off-label Drugs for PE

Exhibit 32             Popular Therapeutics Available for Premature Ejaculation Treatment in Market

Exhibit 33             PE OTC Drugs Marketing Channels

Exhibit 34             Impact of Low Effectiveness of Non-pharmacological PE Treatment

Exhibit 35             Effectiveness of Pharmacotherapy for PE Treatment

Exhibit 36             Major Drawbacks of Non-pharmacological PE Treatments

Exhibit 37             Impact of Increasing Awareness Campaigns & Initiatives for PE Treatment

Exhibit 38             Impact of Availability of Alternative Treatment Options for PE

Exhibit 39             Popular Alternative Methods for PE Treatment

Exhibit 40             Impact of Low Treatment-Seeking Patient Pool

Exhibit 41             Number of Men with PE 2018 (million)

Exhibit 42             Key Factors Restricting PE Treatment Adoption

Exhibit 43             Major Surveys to Indicate Low PE Treatment Seeking Population

Exhibit 44             South Korean Survey Results on Urologists' PE Treatment Rates Per Week in 2012 (%)

Exhibit 45             Impact of Adverse Effects of PE Therapeutics

Exhibit 46             Common Adverse Effects of Drugs Recommended for PE

Exhibit 47             Impact of Clinical Trial Withdrawals/Terminations & Inactive Clinical Studies

Exhibit 48             Key Common Challenges Associated with Clinical Trial Withdrawals/Terminations

Exhibit 49             Global Premature Ejaculation Therapeutics Market Snapshot

Exhibit 50             Global Premature Ejaculation Therapeutics Market 2019–2025 ($ million)

Exhibit 51             Global Premature Ejaculation Therapeutics Market by Geography

Exhibit 52             Global Premature Ejaculation Therapeutics Market by Drug Class

Exhibit 53             Global Premature Ejaculation Therapeutics Market by ROA

Exhibit 54             Five Forces Analysis 2019

Exhibit 55             Incremental Growth by Drug Class 2019 & 2025

Exhibit 56             Global Premature Ejaculation Therapeutics Market by Drug Class

Exhibit 57             Global Market by Drug Class: Incremental Growth

Exhibit 58             Global Market by Drug Class: Absolute Growth

Exhibit 59             Global Market by Drug Class 2019−2025 ($ million)

Exhibit 60             Global Market by Drug Class 2019−2025 (%)

Exhibit 61             Common SSRIs for Treating PE

Exhibit 62             Global PE Therapeutics Market by SSRIs: Incremental & Absolute Growth Comparison

Exhibit 63             Comparison of Varying Efficacy Rates of Off-label SSRIs

Exhibit 64             Global SSRIs Market 2019–2025 ($ million)

Exhibit 65             Global PE Therapeutics Market by PDE5 Inhibitors: Incremental & Absolute Growth Comparison

Exhibit 66             Major PDE5i Drug Brands as Off-label PE Medications

Exhibit 67             Global PDE5 Inhibitors Market 2019–2025 ($ million)

Exhibit 68             Global PE Therapeutics Market by Anesthetic Agents: Incremental & Absolute Growth Comparison

Exhibit 69             Common Active Ingredients in Topical Anesthetic Formulations

Exhibit 70             Global Anesthetic Market 2019–2025 ($ million)

Exhibit 71             Global PE Therapeutics Market by Others Drugs: Incremental & Absolute Growth Comparison

Exhibit 72             Several Drug Classes Used for Treating Premature Ejaculation

Exhibit 73             Global Others Drugs Market 2019–2025 ($ million)

Exhibit 74             Incremental Growth by ROA 2019 & 2025

Exhibit 75             Global Premature Ejaculation Therapeutics Market by ROA

Exhibit 76             Global Market by ROA: Incremental Growth

Exhibit 77             Global Market by ROA: Absolute Growth

Exhibit 78             Global Market by ROA 2019−2025 ($ million)

Exhibit 79             Global Market by ROA 2019−2025 (%)

Exhibit 80             Oral Premature Ejaculation Treatment Market: Incremental & Absolute Growth

Exhibit 81             Major Oral Therapeutics Recommended for PE

Exhibit 82             Advantages of Oral PE Drugs

Exhibit 83             Global Oral PE Therapeutics Market 2019–2025 ($ million)

Exhibit 84             Available Topical Forms of PE Topical Therapies

Exhibit 85             Global PE Therapeutics Market by Topical ROA: Incremental & Absolute Growth

Exhibit 86             Benefits of Topical PE Drugs

Exhibit 87             Global Topical Market 2019–2025 ($ million)

Exhibit 88             Incremental Growth by Geography 2019 & 2025

Exhibit 89             Global Premature Ejaculation Therapeutics Market by Geography

Exhibit 90             Global Market by Geography 2019: Key Countries ($ million)

Exhibit 91             Global Market by Geography: Incremental Growth

Exhibit 92             Global Market by Geography: Absolute Growth

Exhibit 93             Global Market by Geography 2019−2025 ($ million)

Exhibit 94             Global Market by Geography 2019−2025 (%)

Exhibit 95             Premature Ejaculation Therapeutics Market in North America in 2019

Exhibit 96             North America Market: Incremental & Absolute Growth

Exhibit 97             Market in North America 2019–2025 ($ million)

Exhibit 98             Incremental Growth by Drug Class 2019 & 2025

Exhibit 99             North America Market by Drug Class 2019−2025 ($ million)

Exhibit 100          North America Market by Drug Class 2019−2025 (%)

Exhibit 101          Incremental Growth in North America 2019 & 2025

Exhibit 102          Number of People with Various Male Urologic Disorders in US

Exhibit 103          Market in US 2019–2025 ($ million)

Exhibit 104          Market in Canada 2019–2025 ($ million)

Exhibit 105          Premature Ejaculation Therapeutics Market in Europe 2019

Exhibit 106          Europe Market: Incremental & Absolute Growth

Exhibit 107          Market in Europe 2019–2025 ($ million)

Exhibit 108          Incremental Growth by Drug Class 2019 & 2025

Exhibit 109          Europe Market by Drug Class 2019−2025 ($ million)

Exhibit 110          Europe Market by Drug Class 2019−2025 (%)

Exhibit 111          Incremental Growth in Europe 2019 & 2025

Exhibit 112          Prevalence of PE in Men Aged 18−64 Years in Germany (%)

Exhibit 113          Market in Germany 2019–2025 ($ million)

Exhibit 114          Market in UK 2019–2025 ($ million)

Exhibit 115          Market in France 2019–2025 ($ million)

Exhibit 116          Market in Italy 2019–2025 ($ million)

Exhibit 117          Market in Spain 2019–2025 ($ million)

Exhibit 118          APAC Premature Ejaculation Therapeutics Market: Incremental & Absolute Growth

Exhibit 119          Market in APAC 2019

Exhibit 120          Market in APAC 2019–2025 ($ million)

Exhibit 121          Incremental Growth by Drug Class 2019 & 2025

Exhibit 122          APAC Market by Drug Class 2019−2025 ($ million)

Exhibit 123          APAC Market by Drug Class 2019−2025 (%)

Exhibit 124          Incremental Growth in APAC 2019 & 2025

Exhibit 125          Market in Japan 2019–2025 ($ million)

Exhibit 126          Market in India 2019–2025 ($ million)

Exhibit 127          Market in China 2019–2025 ($ million)

Exhibit 128          Market in Australia 2019–2025 ($ million)

Exhibit 129          Market in South Korea 2019–2025 ($ million)

Exhibit 130          Premature Ejaculation Therapeutics Market in Latin America 2019

Exhibit 131          Latin America Market: Incremental & Absolute Growth

Exhibit 132          Market in Latin America 2019–2025 ($ million)

Exhibit 133          Incremental Growth by Drug Class 2019 & 2025

Exhibit 134          Latin America Market by Drug Class 2019−2025 ($ million)

Exhibit 135          Latin America Market by Drug Class 2019−2025 (%)

Exhibit 136          Incremental Growth in Latin America 2019 & 2025

Exhibit 137          Market in Brazil 2019–2025 ($ million)

Exhibit 138          Market in Mexico 2019–2025 ($ million)

Exhibit 139          Market in Argentina 2019–2025 ($ million)

Exhibit 140          Premature Ejaculation Therapeutics Market in MEA 2019

Exhibit 141          MEA Market: Incremental & Absolute Growth

Exhibit 142          Market in MEA 2019–2025 ($ million)

Exhibit 143          Incremental Growth by Drug Class 2019 & 2025

Exhibit 144          MEA Market by Drug Class 2019−2025 ($ million)

Exhibit 145          MEA Market by Drug Class 2019−2025 (%)

Exhibit 146          Incremental Growth in MEA 2019 & 2025

Exhibit 147          Prevalence of PE in Turkish Population (%)

Exhibit 148          Market in Turkey 2019–2025 ($ million)

Exhibit 149          Market in Saudi Arabia 2019–2025 ($ million)

Exhibit 150          Market in South Africa 2019–2025 ($ million)

Exhibit 151          Market in Iran 2019–2025 ($ million)

Exhibit 152          Global Premature Ejaculation Therapeutics Market: Vendors Market Share 2019

Exhibit 153          Pfizer: R&D Expenditure 2017−2019 ($ million)

Exhibit 154          Pfizer: Revenue by Segments 2018 & 2019 ($ million)

Exhibit 155          Pfizer: Revenue by Geography 2018 (%)

               

               

List of Tables    

Table 1                  Key Caveats

Table 2                  Currency Conversion 2013−2019

Table 3                  Popular Definitions of Premature Ejaculation

Table 4                  Summary of PE Epidemiology Studies

Table 5                  Recommended/Optional Questions to Establish Diagnosis and Treatment of PE

Table 6                  Summary of PE Validated Questionnaires

Table 7                  Summary of Commonly Recommended PE Drugs

Table 8                  Key Pipeline PE Drug Molecules

Table 9                  Epelsiban: Product Profile

Table 10               IX-01 Product Profile

Table 11               DA-8031 Product Profile

Table 12               NH02D Product Profile

Table 13               Key Dormant/Terminated/Withdrawn PE Pipeline Drug Molecules

Table 14               Key Topical Therapy PE Drugs by Type of Formulation

Table 15               Major Unmet Need in PE Market

Table 16               Marketed PE Drugs with Meter-Dose Delivery Systems

Table 17               Notable Awareness Campaigns Initiated for PE in Recent Years

Table 18               Key Terminated/Withdrawn & Inactive Investigational PE Drugs

Table 19               SSRIs Dose in PE Treatment

Table 20               List of Popular SSRIs for PE

Table 21               List of Popular PDE5 Inhibitors For PE

Table 22               Commonly Used Topical PE OTC Ester/Amide Anesthetic

Table 23               List of Popular Anesthetic Agents for Treating PE

Table 24               Significant Players Offering Oral Drugs for PE Treatment

Table 25               Comparison of Popular Topical Anesthetics for PE

Table 26               North America Premature Ejaculation Therapeutics Market by Drug Class 2019−2025 ($ million)

Table 27               Key Campaigns Launched in Europe to Improve Awareness of PE

Table 28               Europe Premature Ejaculation Therapeutics Market by Drug Class 2019−2025 ($ million)

Table 29               APAC Premature Ejaculation Therapeutics Market by Drug Class 2019−2025 ($ million)

Table 30               Latin America Premature Ejaculation Therapeutics Market by Drug Class 2019−2025 ($ million)

Table 31               MEA Premature Ejaculation Therapeutics Market by Drug Class 2019−2025 ($ million)

Table 32               Competitive Structure Analysis of Global Premature Ejaculation Therapeutics Market 2019

Table 33               Global Premature Ejaculation Therapeutics Market Vendor Ranking 2019

Table 34               Absorption Pharmaceuticals: Major Product Offerings

Table 35               Innovus Pharmaceuticals: Major Product Offerings

Table 36               Pfizer: Major Product Offerings

Table 37               Plethora Solutions Holdings: Major Product Offerings

Table 38               Bayer: Major Product Offerings

Table 39               Eli Lilly and Company: Major Product Offerings

Table 40               GlaxoSmithKline: Major Product Offerings

Table 41               MidasCare: Major Product Offerings

Table 42               Momentum Management: Major Product Offerings

Table 43               Pound International: Major Product Offerings

Table 44               Reckitt Benckiser Group: Major Product Offerings

Table 45               Recordati: Major Product Offerings

Table 46               Royalty Pharma: Major Product Offerings

Table 47               Shibari: Major Product Offerings

Table 48               The Menarini Group: Major Product Offerings

Table 49               Global Premature Ejaculation Therapeutics Market by Drug Class 2019−2025 ($ million)

Table 50               Global Market by Drug Class 2019−2025 (%)

Table 51               Global Premature Ejaculation Therapeutics Market by ROA 2019−2025 ($ million)

Table 52               Global Market by ROA 2019−2025 (%)

Table 53               Global Premature Ejaculation Therapeutics Market by Geography 2019−2025 ($ million)

Table 54               Global Market by Geography 2019−2025 (%)

Select a license type that suits your business needs

single-user Single User Licence
$3400.00
  • Report accessible by one user only
  • Free 10% or 3 days of customization
  • Free post-sale service assistance
  • Continuous support through email
Best Value Tag
5-user 5 User Licence
$3600.00
  • Report accessible by 5 users within the organization
  • Free 15% or 4.5 days of customization
  • Free post-sale service assistance
  • Continuous support through email and telephone
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
corporate.png Corporate Licence
$4400.00
  • Free Datasheet worth $1500
  • Report accessible by the entire organization
  • Free 20% or 6 days of customization
  • Free post-sale service assistance
  • Continuous support through email and telephone
  • Direct access to lead analysts
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
datasheet.png Datasheet Licence
$1600.00
  • Report accessible by 1 user only
  • Free 15% or 32 hours of customization
  • Free post-sale service assistance
  • Direct access to lead analysts

Our Clients

20%

Off

OFF

DAYS

HOURS

MINUTES

SECONDS

Licence Types What are these?

Interested in data center portfolio for this report?
Click here

Our Clients Speak

erick

"The report by Arizton was spot on. It not only gave us insight into the pro audio market, we used it to raise funds for our company. The data proved (to the VC we pitched to) that the market was large enough for our company to not only survive but also grow."

Erik Young
CEO, Co-founder
Audink Inc., DBA Audios
SPEAK WITH OUR ANALYST

Want to know more about the report or any specific requirement?

Click to Email +1-312-235-2040

Want to Customize the Report?

Click Here

Why Arizton?

  • 100% Customer Satisfaction
  • 24x7 availability – we are always there when you need us
  • 200+ Fortune 500 Companies trust Arizton's report
  • 80% of our reports are exclusive and first in the industry
  • 100% more data and analysis
  • 1000+ reports published till date